NASDAQ · SMFR
Healthcare · Medical - Healthcare Information Services
$0.31
Up+$0.07 (+26.78%)
Updated Aug 15, 2026, 12:11 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
SMFR does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning SMFR.
SMFR research
Company profile and research snapshot.
Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 7, 2022 | Goldman Sachs | Neutral | — |
| Nov 15, 2022 | Cowen & Co. | Outperform | — |
| Aug 18, 2022 | BTIG | Buy | — |
| Aug 16, 2022 | Jefferies | Hold | — |
| May 16, 2022 | Cowen & Co. | Outperform | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Dec 30, 2022
Sema4|GeneDx President & Chief Executive Officer, Katherine Stueland, to deliver presentation Sema4|GeneDx President & Chief Executive Officer, Katherine Stueland, to deliver presentation
Benzinga · Dec 7, 2022
Goldman Sachs downgraded its rating of Sema4 Holdings (NASDAQ:SMFR) to Neutral with a price target of $1.00, changing its price target from $3.00 to $1.00. Shares of Sema4 Holdings are trading down 6.35% over the last 24 hours, at $0.28 per share. A move to $1.00 would account for a 252.86% increase from the current share price. About Sema4 Holdings Sema4 Holdings Corp is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. It is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build ...Full story available on Benzinga.com
Zacks Investment Research · Nov 14, 2022
Sema4 Holdings Corp. (SMFR) delivered earnings and revenue surprises of -5.26% and 8.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswire Inc. · Nov 14, 2022
Company will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing and analysis and data-driven insights from Centrellis®
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SMFR.
No results
No recent SID articles mention SMFR.
